Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 3/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.58 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL167985 | 0.95 | CYP2A6 (0.64) | HPRT1CYP1A2CYP2A6HSD17B10ALDH1A1 | |
| SCHEMBL598782 | 0.91 | HPRT1 (0.64) | HPRT1CYP1A2CYP2A6HSD17B10ALDH1A1 | |
| SCHEMBL28996719 | 0.91 | HPRT1 (0.64) | HPRT1CYP1A2CYP2A6HSD17B10ALDH1A1 | |
| SCHEMBL30540087 | 0.88 | CYP2A6 (0.65) | HPRT1CYP1A2CYP2A6HSD17B10ALDH1A1 | |
| SCHEMBL216959 | 0.88 | CYP2A6 (0.65) | HPRT1CYP1A2CYP2A6HSD17B10ALDH1A1 | |
| SCHEMBL598691 | 0.87 | CYP2A6 (0.58) | HPRT1CYP1A2CYP2A6HSD17B10ALDH1A1 | |
| SCHEMBL598203 | 0.86 | ALDH1A1 (0.59) | HPRT1CYP1A2CYP2A6HSD17B10ALDH1A1 | |
| SCHEMBL598440 | 0.86 | ALDH1A1 (0.59) | HPRT1CYP1A2CYP2A6HSD17B10ALDH1A1 | |
| SCHEMBL23366571 | 0.85 | HPRT1 (0.52) | HPRT1CYP1A2CYP2A6HSD17B10ALDH1A1 | |
| SCHEMBL23366562 | 0.85 | HPRT1 (0.52) | HPRT1CYP1A2CYP2A6HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540073-B2 | Heterogeneous hydrogen-catalyst solid fuel reaction mixture and reactor | BRILLIANT LIGHT POWER, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-12227625-B2 | Composite materials comprising mechanical ligands | NANOCORE APS (DK) | 2025-02-18 | — | — | US | disclosed |
| US-20230045778-A9 | HETEROGENEOUS HYDROGEN-CATALYST SOLID FUEL REACTION MIXTURE AND REACTOR | BRILLIANT LIGHT POWER, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| EP-4119598-A1 | NANOCOMPOSITE MATERIALS COMPRISING MECHANICAL LIGANDS | Nanocore ApS (DK) | 2023-01-18 | — | — | EP | disclosed |
| EP-3737711-B1 | COMPOSITE MATERIALS COMPRISING MECHANICAL LIGANDS | NANOCORE APS (DK) | 2022-04-06 | — | — | EP | disclosed |
| EP-3737711-A1 | COMPOSITE MATERIALS COMPRISING MECHANICAL LIGANDS | Nanocore Aps (DK) | 2020-11-18 | — | — | EP | disclosed |
| US-20200354220-A1 | COMPOSITE MATERIALS COMPRISING MECHANICAL LIGANDS | NANOCORE APS (DK) | 2020-11-12 | — | — | US | disclosed |
| US-20200299130-A1 | HETEROGENEOUS HYDROGEN-CATALYST REACTOR | BRILLIANT LIGHT POWER, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-8557565-B2 | Degradation of polycyclic aromatic hydrocarbons to render them available for biodegradation | WAVREK DAVID (US) | 2013-10-15 | — | — | US | disclosed |
| US-8298814-B1 | Degradation of polycyclic aromatic hydrocarbons | Wavrek, David A. (US) | 2012-10-30 | — | — | US | disclosed |
| EP-1461041-A4 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD (BB) | 2006-03-29 | — | — | EP | disclosed |
| EP-1569652-A2 | N SP 4 /SP-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | Pharmasset Ltd. (BB) | 2005-09-07 | — | — | EP | disclosed |
| US-6908924-B2 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | PHARMASSET, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20040214844-A1 | N4-acylcytosine nucleosides for treatment of viral infections | GILEAD PHARMASSET LLC | 2004-10-28 | — | — | US | disclosed |
| EP-1461041-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | Pharmasset Ltd. (BB) | 2004-09-29 | — | — | EP | disclosed |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | GILEAD PHARMASSET LLC | 2003-09-18 | — | — | US | disclosed |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | PHARMASSET, INC. | 2003-08-28 | — | — | US | disclosed |
| WO-2003063771-A2 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | PHARMASSET LTD. (BB) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003051298-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051306-A2 | N4-ACYLCYTOSINE-1,3-DIOXOLANE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | ENTPD5, CDA, ADA | HPRT1 21/4885CYP1A2 810/4885CYP2A6 1101/4885 |
| US-20040214844-A1 | N4-acylcytosine nucleosides for treatment of viral infections | ENTPD5, DUT, PNP | HPRT1 58/4885CYP1A2 1161/4885CYP2A6 1193/4885 |
| US-12540073-B2 | Heterogeneous hydrogen-catalyst solid fuel reaction mixture and reactor | SCO2, SOD1, HAO2 | HPRT1 3652/4885CYP1A2 1592/4885CYP2A6 4027/4885 |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | DERA, DPYD, DHPS | HPRT1 183/4885CYP1A2 592/4885CYP2A6 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.